T-cell Lymphoma Treatment Market

T-cell Lymphoma Treatment Market - Global Industry Analysis 2014 - 2018 and Forecast, 2019 - 2029

ID: PMRREP29911| | Upcoming | Format: PDF, Excel, PPT* | Healthcare

Market Growth and Regional Outlook Report by Persistence Market Research

Market Overview

Cutaneous T-cell lymphoma is a rare cancer that begins in WBC (T lymphocytes). The T lymphocytes are key to the immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities resulting them to attack the skin. Cutaneous T-cell lymphoma is of two types, Mycosis fungoides and Sézary syndrome.

Mycosis fungoidesis the most common type of Cutaneous T-cell lymphoma diagnosed while Sézary syndrome is more aggressive type. Localized mycosis fungoides may benefit from a number of therapeutic options including intralesional steroids, radiotherapy, or surgical excision.

Although many a time’s Cutaneous T-cell lymphoma is misdiagnosed as eczema, the diagnosis rate is increasing. The most common methods of diagnosis include physical exam, blood tests, skin biopsies, and imaging tests.

Cutaneous T-cell lymphoma treatment are available in many forms to patients. Some of the Cutaneous T-cell lymphoma treatment options include skin creams and ointments, light therapy, radiation therapy, medications, and bone marrow transplant. Some patients also opt for home remedies such as use of mild unscented soap, use of skin lotions, and bleach bath to treat the irritated skin.

Combination chemotherapy treatment is generally not preferred for mycosis fungoides, due to the infectious complications and short response duration, outweigh the modest response rates seen in this disease.

Cutaneous T-cell lymphoma treatment when diagnosed early primarily consists of topical treatments such as retinoids, corticosteroids and chemotherapy. Some of the FDA approved cutaneous T-cell lymphoma treatment regimens include use of topical Bexarotene gel, Mechlorethamine gel, local radiation and ultraviolet light.

Some of the systemic cutaneous T-cell lymphoma treatments that are approved include, Acitretin, Bexarotene capsules, Methotrexate tablets, Romidepsin, and Vorinostat.

The report covers exhaustive analysis

  • Cutaneous T-cell Lymphoma Treatment Market Segments
  • Cutaneous T-cell Lymphoma Treatment Market Dynamics
  • Historical Actual Cutaneous T-cell Lymphoma Treatment Market Size, 2014 - 2018
  • Cutaneous T-cell Lymphoma Treatment Market Size & Forecast 2019 to 2029
  • Cutaneous T-cell Lymphoma Treatment Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Cutaneous T-cell Lymphoma Treatment Market Drivers and Restraints

Report Highlights

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Market Segmentation

Drug Type
  • Topical products
    • Bexarotene gel
    • Mechlorethamine gel
  • Systemic products
    • Acitretin
    • Bexarotene capsules
    • Methotrexate tablets
    • Romidepsin
    • Vorinostat
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Delivery Timelines
For more information on this report and its delivery timelines please get in touch with our sales team.

We use cookies to improve user experience.
Google translate